Early Oral & Topical Anti-inflammatory Therapies for IBD
Budesonide / A registered trademark owned by Tillotts Pharma AG, used under license by Pendopharm, division of Pharmascience Inc. (2016)
Controlled ileal release capsules indicated for the treatment of mild-to-moderate active Crohn’s disease involving the ileum and/or the ascending colon.
Oral
Induction: 9 mg daily for up to 8 weeks.
Maintenance: 6 mg daily for up to 3 months for maintenance of clinical remission.
Induction10-11: 9 mg once daily for 8 weeks, followed by 6 mg daily for 4 weeks.
Maintenance: Not recommended.
RCTs: randomized clinical trials, IV: intravenous, BDP: beclomethasone dipropionate
For more detailed information regarding side effects, please refer to the appropriate product monograph.
• Hypertension
• Acne vulgaris
• Cushingoid appearance
• Nausea
• Bruising
• Headache
• Respiratory tract infection
• Dysuria
• Infection
• Mood changes
• Peptic ulcer
IBD: inflammatory bowel disease
Safety and effectiveness in children have not been established.
No data for Health Canada to review.
ECCO Crohn’s guidelines13:
In children with mild to moderate ileo-cecal Crohn’s disease budesonide may be used as an alterative to systemic corticosteroids for induction of remission.
Product monograph: no acknowledgement of the older population.
Recommendations14:
May be preferred over conventional corticosteroids in older patients with ileocolonic or right sided luminal Crohn’s disease.
Coming soon
Coming soon
IBD: inflammatory bowel disease, 5-ASA: 5-aminosalicylic acid, ECCO: European Crohn’s and Colitis Organization, EEN: enteral nutrition